By

Luke Timmerman

25
Mar
2021

A Glimpse Into a Price-Controlled Future

Imagine if H.R. 3 — the drug price-control bill that has significant support in the House of Representatives — were to become law. What would it look like if some of the bill’s provisions, like indexing US prices to 120 percent of prices in Europe, were enacted? How would entrepreneurs adapt? What types of drug discovery programs might be prioritized,...
Read More
15
Mar
2021

Software for the Cell & Gene Therapy Wave: Vineti’s Amy DuRoss on The Long Run

Today’s guest on The Long Run is Amy DuRoss. Amy is the co-founder and CEO of San Francisco-based Vineti. The company provides software to manage the delicate logistical dance for cell and gene therapies. Vineti has raised about $115 million in three venture rounds of financing. Its backers include Cardinal Health, the big medical distributor, as well as traditional venture...
Read More